Artwork

Контент предоставлен Proactive Investors. Весь контент подкастов, включая эпизоды, графику и описания подкастов, загружается и предоставляется непосредственно компанией Proactive Investors или ее партнером по платформе подкастов. Если вы считаете, что кто-то использует вашу работу, защищенную авторским правом, без вашего разрешения, вы можете выполнить процедуру, описанную здесь https://ru.player.fm/legal.
Player FM - приложение для подкастов
Работайте офлайн с приложением Player FM !

Solvonis Therapeutics chairman on the future of biotech & neuroscience M&A

8:25
 
Поделиться
 

Manage episode 463984746 series 2891889
Контент предоставлен Proactive Investors. Весь контент подкастов, включая эпизоды, графику и описания подкастов, загружается и предоставляется непосредственно компанией Proactive Investors или ее партнером по платформе подкастов. Если вы считаете, что кто-то использует вашу работу, защищенную авторским правом, без вашего разрешения, вы можете выполнить процедуру, описанную здесь https://ru.player.fm/legal.
Solvonis Therapeutics PLC chairman Dennis Purcell talked with Proactive's Stephen Gunnion about the increasing mergers and acquisitions (M&A) activity in the neuroscience sector. He highlighted how large pharmaceutical companies are shifting their focus to neurological disorders, investing billions in biotech firms working on conditions like schizophrenia, depression, and addiction. Purcell pointed to major deals, such as Pfizer’s $14 billion acquisition of Karuna for its schizophrenia treatment and Eli Lilly’s $9 billion purchase of Intra-Cellular Therapies. He emphasised that pharmaceutical companies are now prioritising "de-risked assets" with clear proof of concept before making acquisitions. Discussing broader trends, Purcell noted that the biotech sector has seen a significant increase in companies over the past decade, rising from 2,000 to 6,000. He believes industry consolidation—whether through big pharma acquisitions or biotech-to-biotech mergers—will drive efficiency and attract more venture capital. Additionally, Purcell addressed advancements in Huntington’s disease treatments, with three promising compounds nearing potential approval. He also sees growing interest in psychedelic-based therapies for mental health conditions, despite some setbacks in 2024. With thousands of ongoing gene therapy trials, Purcell stressed the need for companies to present clear investment cases to attract funding. He remains optimistic that 2025 will bring increased investor interest in neuroscience breakthroughs. 🔔 Subscribe to Proactive’s YouTube channel for more expert insights. Don’t forget to like this video and enable notifications for updates on the latest biotech and pharma news. #Biotech #Neuroscience #PharmaInvesting #MergersAndAcquisitions #GeneTherapy #MentalHealth #BiotechStocks #SolvonisTherapeutics #BigPharma #DrugDevelopment #InvestorInsights
  continue reading

605 эпизодов

Artwork
iconПоделиться
 
Manage episode 463984746 series 2891889
Контент предоставлен Proactive Investors. Весь контент подкастов, включая эпизоды, графику и описания подкастов, загружается и предоставляется непосредственно компанией Proactive Investors или ее партнером по платформе подкастов. Если вы считаете, что кто-то использует вашу работу, защищенную авторским правом, без вашего разрешения, вы можете выполнить процедуру, описанную здесь https://ru.player.fm/legal.
Solvonis Therapeutics PLC chairman Dennis Purcell talked with Proactive's Stephen Gunnion about the increasing mergers and acquisitions (M&A) activity in the neuroscience sector. He highlighted how large pharmaceutical companies are shifting their focus to neurological disorders, investing billions in biotech firms working on conditions like schizophrenia, depression, and addiction. Purcell pointed to major deals, such as Pfizer’s $14 billion acquisition of Karuna for its schizophrenia treatment and Eli Lilly’s $9 billion purchase of Intra-Cellular Therapies. He emphasised that pharmaceutical companies are now prioritising "de-risked assets" with clear proof of concept before making acquisitions. Discussing broader trends, Purcell noted that the biotech sector has seen a significant increase in companies over the past decade, rising from 2,000 to 6,000. He believes industry consolidation—whether through big pharma acquisitions or biotech-to-biotech mergers—will drive efficiency and attract more venture capital. Additionally, Purcell addressed advancements in Huntington’s disease treatments, with three promising compounds nearing potential approval. He also sees growing interest in psychedelic-based therapies for mental health conditions, despite some setbacks in 2024. With thousands of ongoing gene therapy trials, Purcell stressed the need for companies to present clear investment cases to attract funding. He remains optimistic that 2025 will bring increased investor interest in neuroscience breakthroughs. 🔔 Subscribe to Proactive’s YouTube channel for more expert insights. Don’t forget to like this video and enable notifications for updates on the latest biotech and pharma news. #Biotech #Neuroscience #PharmaInvesting #MergersAndAcquisitions #GeneTherapy #MentalHealth #BiotechStocks #SolvonisTherapeutics #BigPharma #DrugDevelopment #InvestorInsights
  continue reading

605 эпизодов

Kaikki jaksot

×
 
Loading …

Добро пожаловать в Player FM!

Player FM сканирует Интернет в поисках высококачественных подкастов, чтобы вы могли наслаждаться ими прямо сейчас. Это лучшее приложение для подкастов, которое работает на Android, iPhone и веб-странице. Зарегистрируйтесь, чтобы синхронизировать подписки на разных устройствах.

 

Краткое руководство

Слушайте это шоу, пока исследуете
Прослушать